Why Isn’t My GLP-1 Working? What to Review With Your Provider

When weight loss is slower than expected, it can be frustrating. But “not working” can mean different things: little weight change, persistent hunger, or side effects that make treatment difficult. Review what is happening with your prescribing clinician rather than judging your response against someone else’s experience. ^{[1] [4]}

An unexpected response is a reason for clinical review—not proof that your DNA makes the medication ineffective. Genetics can contribute to medication response, but it is only one part of a much larger clinical picture. ^[7]

What to review before calling treatment unsuccessful

Treatment duration and the prescribed plan

For semaglutide injection, clinicians generally start at a lower dose and increase it gradually. Ask whether you are still in dose escalation and when your clinician plans to evaluate your response. Follow the instructions for your exact prescribed product; do not increase the dose or take it more often on your own. ^[2]

Medication use, supply, and instructions

Tell your care team about missed doses, delayed refills, or uncertainty about administration. Ask the pharmacist to confirm the instructions for the actual product you received, including measurement and storage. FDA has reported serious dosing errors with compounded injectable semaglutide, so unclear instructions should be resolved—not guessed at. ^{[2] [3]}

Your health history and nutritional needs

Review other medications, supplements, and relevant health conditions with your clinician. These are part of deciding whether a treatment remains appropriate and whether an alternative should be considered. ^[1]

Nutrition and activity also deserve an individualized review. A multisociety advisory emphasizes managing gastrointestinal symptoms, maintaining adequate nutrition, and supporting muscle health during GLP-1 treatment. This review should address barriers and tolerability—not simply tell you to eat less. ^[5]

Progress over time and the goals of treatment

Agree on the outcomes and time frame you will review together. Weight matters, but blood pressure, other relevant health measures, and daily function may matter too. If progress is not meeting your goals, ask for a reassessment rather than continuing indefinitely without follow-up. ^[4]

What genetics research actually shows

A 2025 study by Cleveland Clinic and NIH researchers examined an NBEA genetic score and weight change among people prescribed GLP-1 receptor agonists. The researchers used the NIH All of Us cohort and UK Biobank. Associations varied by medication; notably, the non-response score did not validate for semaglutide. ^[6]

This was an observational analysis, not a trial showing that test-guided treatment improved outcomes. It does not establish that genetics alone explains an individual’s response. It evaluates an NBEA score—not the PlexusDx report—and does not validate a different panel or recommendations for additional peptides. ^[6]

The appropriate conclusion is that genetics is an active area of research. A study’s findings must stay tied to the score, medication, population, and outcome actually studied—not become a general promise that a commercial report will explain treatment failure.

Why a pathway finding is not a diagnosis of non-response

A variant associated with metabolism or appetite is not automatically a validated predictor of medication response. Evidence that a laboratory accurately identifies a variant is also different from evidence that using the result improves a treatment decision. ^{[7] [8]}

CLIA certification addresses laboratory quality. It does not, by itself, establish the clinical validity or usefulness of a genetic interpretation. Similarly, a result described as “higher risk” for a trait should not automatically be translated into “this medication will not work.” ^[8]

Pharmacogenetics has established uses for some medicines. Those uses do not validate every pathway-based report or make genetic testing a prerequisite for every prescription. ^[7]

The role—and limits—of the PlexusDx report

The PlexusDx GLP-1 & Peptide Pathways Report presents selected genetic findings in pathway-based categories and states that its intended use is wellness education. ^[10]

Within that scope, it should not be used to diagnose medication non-response, label someone a “genetic non-responder,” choose between semaglutide and tirzepatide, determine dosing, or identify another peptide to add. This article does not claim that purchasing the report improves weight loss or treatment outcomes.

Discuss questions about a genetic finding with a qualified healthcare professional, but do not delay a medication review while waiting for a genetic explanation. Consumer genetic information is not a substitute for clinical evaluation. ^[9]

A genetic result does not justify an unapproved add-on

Genetic information does not change a compound’s regulatory status or establish that it is safe or effective. FDA states which compounds can and cannot be used in compounding under federal law.  In addition, compounded medications are not FDA-approved. A pathway finding alone does not establish that an FDA-approved treatment cannot meet a patient’s medical needs. ^[3]

When to seek medical help promptly

Seek urgent medical care for severe, persistent abdominal pain or repeated vomiting with inability to keep fluids down. Call 911 for trouble breathing or swelling of the face or throat. These are safety concerns, not reasons to wait for genetic testing. ^[2]

Frequently asked questions

Should I increase my dose if I still feel hungry?

Do not change the dose or schedule yourself. Tell your prescriber what you are experiencing and follow their instructions for your medication. ^[2]

Should I buy this report to find out why I am not losing weight?

This report should not be purchased for the purpose of diagnosing medication non-response. The next step is a review with your prescribing clinician. A separate genetic test should be considered only for a specific clinical question with evidence supporting that use. ^[9]

Does slow weight loss mean the treatment has no benefit?

Not necessarily. Your clinician should assess the goals for which the medication was prescribed and weigh benefits against risks. That is not a reason to ignore a lack of progress or continue treatment without reassessment. ^{[1] [4]}

Your next step

Arrange a follow-up with your prescribing clinician. Bring your medication name, start date, dose history, any missed doses, weight trend, and side-effect notes. Ask what would count as an adequate response and when the plan should be reconsidered. ^{[1] [4]}

To understand the scope of the GLP-1 & Peptide Pathways Genetic Test or Report, review their descriptions and limitations. These are genetic-information products, not a diagnosis of treatment failure or a prescription for another medication.

This article provides general education, not individualized medical advice. Do not start, stop, or change prescribed medication based on a consumer genetic report. ^[9]

Sources

Clinical references support the general educational discussion. They are not endorsements or validation of the PlexusDx report. The PlexusDx product page is cited only for its stated product scope.

1. NIDDK. Prescription Medications to Treat Overweight & Obesity.
2. MedlinePlus. Semaglutide Injection: Drug Information.
3. FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
4. NIDDK. Talking with Your Patients about Weight.
5. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory. American Journal of Clinical Nutrition. 2025;122(1):344–367. doi:10.1016/j.ajcnut.2025.04.023.
6. Mariam-Smith A, et al. Neurobeachin (NBEA) is a novel gene associated with GLP-1 receptor agonist associated weight loss. Diabetes, Obesity and Metabolism. 2025;27(10):5632–5642. doi:10.1111/dom.16612.
7. FDA. Table of Pharmacogenetic Associations.
8. MedlinePlus Genetics. How can I be sure a genetic test is valid and useful?
9. FDA. Direct-to-Consumer Tests.
10. PlexusDx. GLP-1 & Peptide Pathways Report. Source for the stated product scope only; not independent clinical evidence.